Concert Pharmaceuticals, Inc. Expands Management Team

Appointment of Two Executives to Support Advancement of Product Pipeline: Christine Boisclair Named Vice President, Regulatory Affairs, and Scott Weintraub Named Vice President, Commercial and Product Strategy

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the expansion of its senior management team with the appointment of executives in regulatory affairs and commercial strategy to serve in leadership roles as the Company advances its clinical pipeline. Christine Boisclair has been appointed as Vice President, Regulatory Affairs, with primary responsibility for planning and coordinating Concert’s regulatory submissions to the U.S. Food and Drug Administration (FDA) and other regulatory authorities. She replaces Mark Roessel, who recently retired following a long and successful career in the pharmaceutical industry. Scott Weintraub has joined Concert in the newly created position of Vice President, Commercial and Product Strategy, with responsibilities including overseeing the Company’s commercial strategy and market assessments for Concert’s drug candidates and pipeline.

“We are delighted that Christine and Scott will contribute their expertise and talents to Concert’s success in our next stage of growth as we continue to advance our product candidates toward approval”

“We are delighted that Christine and Scott will contribute their expertise and talents to Concert’s success in our next stage of growth as we continue to advance our product candidates toward approval,” said Roger Tung, Ph.D., President and CEO of Concert Pharmaceuticals, Inc. “The addition of these outstanding leaders to our management team reflects the substantial progress we have made to date with our product candidates for the treatment of cystic fibrosis and alopecia areata.”

Christine Boisclair, Vice President, Regulatory Affairs
Ms. Boisclair joins Concert with more than 30 years of regulatory affairs experience in the biopharmaceutical industry across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs, at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals, she held management roles at several companies including Insmed, Agennix, OSI Pharmaceuticals, Genzyme Corporation, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair also worked in regulatory at Searle Pharmaceuticals and Glaxo in the U.K. She received a Bachelor of Science Honors Degree in Biochemistry from the University of York in the U.K.

Scott Weintraub, Vice President, Commercial and Product Strategy
Mr. Weintraub joins Concert with more than 17 years of commercial experience in the biopharmaceutical industry, including strategic product assessment, brand positioning, commercial life cycle management, and sales and marketing. Prior to joining Concert, he was Vice President of Product Strategy and Marketing at Forum Pharmaceuticals. He also served as Senior Director of Marketing at Sunovion Pharmaceuticals and held sales and marketing positions at AstraZeneca. He holds a B.S. in Finance and Marketing from Florida State University and an M.B.A. in Health Administration and Policy from University of Miami.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, central nervous systems (CNS) disorders, as well as autoimmune and inflammatory diseases. For more information please visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.